Abstract The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifte...
Chao-Qi Zhang, Xuan-Yu Gu, Pan-Hong Wang et al.· Ca· 1 citation
It is established that combined KRAS and BCL-2 inhibition elicits pyroptosis and TLS formation, leading to B-cell-dependent in situ and memory antitumor immunity, providing a mechanistic rationale for targeting mitochondrial-immune crosstalk in KRAS G12D-mutant lung cancer.
Xu Yang, Man Li, Jian Zhang et al.· bioRxiv· 0 citations
In this issue of Cancer Cell, Li et al. report a first-in-human phase 1 study of SYS6010, an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate, in advanced solid tumors. The study highlights how EGFR-directed therapy moves beyond kinase inhibition toward antigen-guided cytotoxic delivery in non-...
Li-Hui Liu, Kai-Lun Fei, Jie Wang· Cancer Cell· 0 citations
Abstract The expanding clinical use of Antibody-Drug Conjugates (ADCs) necessitates a clearer understanding of their real-world toxicity profiles across diverse clinical settings. This retrospective pharmacovigilance study analyzed 19,697 adverse event (AE) reports for seven approved ADCs from the FDA Adverse Event Rep...
Linjie Fan, Yu-Ze Yin, W. Zhuang et al.· Drug Delivery· 0 citations
Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy and establish a clinically applicable model for early prediction and risk stratification of SCLC transformation.